ICOS and melanoma: We also identified several major putative regulators, such as LINC00861, CHRM3-AS2, MEG3 and RP11−115D19.1, which correlated with multiple mRNAs, as well as three mRNAs that we speculate can be regulated by two or more ceRNAs in the context of melanoma resistance to nivolumab: ICOS, PAX3, HLA−DOA and HLA−DPB1.